LIF as a known pro-remyelination factor could exert a beneficial effect in the circumstance of a toxic oligodendrocytopathy and also could potentially protect oligodendrocytes in the context of MS, especially in active plaques where the blood–brain barrier is acutely disrupted52. Here, LIF is linked to myeloid sarcoma.